Replimune Group (NASDAQ:REPL) Raised to Buy at Zacks Investment Research

Replimune Group (NASDAQ:REPL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports. The brokerage currently has a $17.00 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.29% from the stock’s current price.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

REPL has been the subject of several other research reports. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and cut their price target for the company from $27.00 to $26.00 in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Replimune Group in a report on Monday, September 30th. ValuEngine cut Replimune Group from a “hold” rating to a “sell” rating in a report on Monday. Roth Capital began coverage on Replimune Group in a report on Wednesday, September 4th. They set a “buy” rating and a $20.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of Replimune Group in a report on Thursday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.50.

Shares of REPL opened at $15.14 on Friday. The business’s 50 day moving average is $13.10 and its 200 day moving average is $13.31. The company has a market capitalization of $467.71 million, a PE ratio of -11.38 and a beta of 3.23. Replimune Group has a 12-month low of $8.88 and a 12-month high of $18.25.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, equities research analysts predict that Replimune Group will post -1.52 EPS for the current year.

In related news, COO Colin Love sold 11,250 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $191,812.50. Also, Chairman Philip Astley-Sparke sold 14,500 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $247,225.00. In the last quarter, insiders sold 50,000 shares of company stock valued at $852,500. Company insiders own 63.18% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. Emerald Mutual Fund Advisers Trust raised its holdings in Replimune Group by 0.5% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock valued at $10,435,000 after acquiring an additional 3,650 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Replimune Group by 211.3% during the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after buying an additional 15,672 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Replimune Group by 1.2% during the 2nd quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock worth $1,817,000 after buying an additional 1,437 shares during the last quarter. Foresite Capital Management III LLC increased its holdings in shares of Replimune Group by 4.0% during the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after buying an additional 30,002 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Replimune Group by 8.2% during the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after buying an additional 76,540 shares during the last quarter. Institutional investors own 60.74% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Article: Understanding the different types of bonds

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.